This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Anacor Pharmaceuticals Is Not for Everyone

NEW YORK (TheStreet) -- I have been talking about, writing about and, most important, investing in stocks for my clients and myself for a long time. You do not have to be a scientist or doctor to invest in scientific or medical progress.

Of the nearly 3,800 stocks I cover in my database, most do not get white-hot overnight. Neither do they lose all their value overnight.

So I look for industries first, then companies within those industries when I am selecting investments. I use the database that I created to select the Best Stocks Now.

That is how I found Anacor Pharmaceuticals (ANAC - Get Report).

Data from Best Stocks Now App

I didn't hear about ANAC from a televised talking head. Nor did I read about it in the Wall Street Journal or Barron's. I found it while scouring the database that I created.

ANAC is in the atopic dermatitis business. Eczema. One of its products is getting some good results and some even say it could be a new standard of treatment for this disease. But just because something is a good company in a good industry with a good even great product, it does not necessarily mean it is a good stock.

ANAC became public in 2010 at $5 per share. I noticed it three months ago when it hit #23 based on my proprietary grading system. Looking at the chart, we see it has done a powerful saucer pattern from April until Mid-August of this year when ANAC broke out and rose up the ranks in my database.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
ANAC $64.49 0.00%
AAPL $130.28 0.00%
FB $81.53 0.00%
GOOG $565.06 0.00%
TSLA $218.42 0.00%

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs